Changeflow GovPing Healthcare & Life Sciences Mitomycine Substipharm 20 mg Filter Update for ...
Routine Notice Amended Final

Mitomycine Substipharm 20 mg Filter Update for Injection Administration

Favicon for ansm.sante.fr ANSM Drug & Device Safety Alerts
Published
Detected
Email

Summary

ANSM issued an updated safety notice for Mitomycine Substipharm 20 mg, permanently including a Millex HV filter (0.45 μm / PVDF) with reconstitution vials. The agency clarified that filtration remains mandatory for intravenous, intra-arterial, and intra-serous administration but is no longer required for intravesical administration. Healthcare professionals in urology, oncology, and related specialties should update their administration protocols accordingly.

Published by ANSM on ansm.sante.fr . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

ANSM updated its 2021 safety guidance on Mitomycine Substipharm 20 mg filtering requirements. The Millex HV filter (0.45 μm / PVDF) is now permanently included with the product. Filtering requirements vary by route: filtration is required for IV, intra-arterial, and intra-serous administration; it is explicitly no longer required for intravesical administration. The agency states filtering does not alter mitomycin C concentration or efficacy.

Hospital pharmacists, urologists, oncologists, and clinical staff should immediately review and update their preparation and administration protocols for Mitomycine Substipharm 20 mg. Ensure staff are trained on the new filtering requirements specific to each administration route. Only the Millex HV filter should be used; alternative filters are not recommended.

What to do next

  1. Update hospital pharmacy protocols for Mitomycine Substipharm 20 mg to reflect permanent filter inclusion
  2. Train clinical staff on route-specific filtration requirements: required for IV/arterial/serous, not required for intravesical
  3. Discontinue use of alternative filters and transition to the supplied Millex HV (0.45 μm / PVDF) only

Archived snapshot

Apr 1, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

A+ A-

Information destinée aux pharmaciens hospitaliers, praticiens et cliniciens en urologie et oncologie
- Le filtre Millex HV (0,45 μm / PVDF) est désormais fourni de façon pérenne avec le flacon à reconstituer. La filtration du médicament ne modifie pas la quantité de la mitomycine C en solution et n’altère pas l’efficacité du médicament.
- La filtration est requise lors de l’administration intraveineuse, intra-artérielle et intra-séreuse.
- Elle n’est plus requise pour une administration par voie intravésicale.
- L’utilisation d’un autre filtre n’est pas recommandée.
Téléchargez le courrier destiné aux professionnels de santé (01/04/2026) RISQUES MEDICAMENTEUX Médicaments Publié le 17/12/2021 ##### Mitomycine Substipharm 20 mg : utilisation d’un filtre pour éviter les réactions liées à l’injection de particules

Information destinée aux pharmaciens hospitaliers, praticiens et cliniciens en urologie, oncologie et ophtalmologie

Named provisions

Filtering Modalities Update Administration Route Requirements

Get daily alerts for ANSM Drug & Device Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from ANSM.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
ANSM
Published
April 1st, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Supersedes
Mitomycine Substipharm 20 mg : utilisation d'un filtre pour éviter les réactions liées à l'injection de particules (December 2021)

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers
Activity scope
Drug Administration Pharmaceutical Safety Clinical Protocol Management
Geographic scope
France FR

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Drug Safety Healthcare Provider Operations

Get alerts for this source

We'll email you when ANSM Drug & Device Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!